incretin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
A 2019 systematic review suggests, based on very limited evidence, that oral administration (swallowing) of glucose (tabs) leads to a bigger improvement in blood glucose levels when compared to buccal administration (dextrose gel). This same review reported that, based on limited evidence, no difference was found in plasma glucose when administering combined oral and buccal glucose compared to only oral administration. In the very specific setting of children with concomitant malaria or respiratory tract infection, sublingual administration of sucrose (table sugar) may be more effective than oral administration. This entails dissolving the table sugar under the tongue.
The 2013 AFL season was the 117th season of the Australian Football League (AFL), the highest level senior Australian rules football competition in Australia, which was known as the Victorian Football League until 1989. The season featured eighteen clubs, ran from 22 March until 28 September, and comprised a 22-game home-and-away season followed by a finals series featuring the top eight clubs. The premiership was won by the Hawthorn Football Club for the eleventh time, after it defeated Fremantle by 15 points in the 2013 AFL Grand Final. The season was marred by a series of off-field controversies, with three clubs penalised in 2013 for separate infractions which had taken place over previous years: Essendon, following an Australian Sports Anti-Doping Authority investigation into the club's supplements program; Adelaide, after illegal payments and draft-tampering charges relating to Kurt Tippett's 2009 contract extension; and Melbourne, after an investigation into allegations that the club had intentionally lost matches towards the end of the 2009 season.
=== Smoking cessation === Prescribed as an aid for smoking cessation, bupropion reduces the severity of craving for nicotine and withdrawal symptoms such as depressed mood, irritability, difficulty concentrating, and increased appetite. Initially, bupropion slows the weight gain that often occurs in the first weeks after quitting smoking. With time, however, this effect becomes negligible. The bupropion treatment course lasts for seven to twelve weeks, with the patient halting the use of tobacco about ten days into the course. After the course, the effectiveness of bupropion for maintaining abstinence from smoking declines over time, from 37% of tobacco abstinence at three months to 20% at one year. It is unclear whether extending bupropion treatment helps to prevent relapse of smoking. Overall, six months after the therapy, bupropion increases the likelihood of quitting smoking approximately 1.6-fold as compared to placebo. In this respect, bupropion is as effective as nicotine replacement therapy but inferior to varenicline. Combining bupropion and nicotine replacement therapy does not improve the quitting rate. In children and adolescents, the use of bupropion for smoking cessation does not appear to offer any significant benefits. The evidence for its use to aid smoking cessation in pregnant women is insufficient.
Angelicin synthase is a cytochrome P450 protein containing heme, isolated from parsnip. It uses molecular oxygen for the oxidation and requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
We were only supposed to carry four passengers ... We had six." According to Maluțan, it was 12:08 when they left for Snagov. After they arrived there, Ceaușescu took Maluțan into the presidential suite and ordered him to get two helicopters filled with soldiers for an armed guard, and a further Dauphin to come to Snagov. Maluțan's unit commander replied on the phone, "There has been a revolution ... You are on your own ... Good luck!" Maluțan then said to Ceaușescu that the second motor was now warmed up and they needed to leave soon but he could only take four people, not six. Mănescu and Bobu stayed behind. Ceaușescu ordered Maluțan to head for Titu. Near Titu, Maluțan says that he received the national flights denial and had to land to not get shot down by the army. He did so in a field next to the old road that led to Pitești. Maluțan then told his four passengers that he could do nothing more. The Securitate men ran to the roadside and began to flag down passing cars. Two cars stopped, one of them driven by a forestry official and one a red Dacia driven by a local doctor. However, the doctor was not happy about getting involved and, after a short time driving the Ceaușescus, faked engine trouble. A bicycle repairman was then flagged down and drove them in his car to Târgoviște. The repairman, Nicolae Petrișor, convinced them that they could hide in an agricultural technical institute on the edge of town. When they arrived, the director there guided the Ceaușescus into a room and then locked them in.
Sources: en.wikipedia.org
Offensive realists accept that threatened states usually balance against dangerous foes, however, they maintain that balancing is often inefficient and that this inefficiency provides opportunities for a clever aggressor to take advantage of its adversaries. Buck passing, rather than joining a balancing coalition, is another tactic offensive realists point to when disputing the balance of power theory. Offensive realists believe that internal balancing measures such as increasing defense spending, implementing conscription, are only effective to a certain extent as there are usually significant limits on how many additional resources a threatened state can muster against an aggressor. However, since offensive realists theorize that states are always seeking to maximize their power, states are "effectively engaged in internal balancing all the time".
mRNA vaccines offer specific advantages over traditional vaccines. Because mRNA vaccines are not constructed from an active pathogen (or even an inactivated pathogen), they are non-infectious. In contrast, traditional vaccines require the production of pathogens, which, if done at high volumes, could increase the risks of localized outbreaks of the virus at the production facility. Another biological advantage of mRNA vaccines is that since the antigens are produced inside the cell, they stimulate cellular immunity, as well as humoral immunity. mRNA vaccines have the production advantage that they can be designed swiftly. Moderna designed their mRNA-1273 vaccine for COVID-19 in 2 days. They can also be manufactured faster, more cheaply, and in a more standardized fashion (with fewer error rates in production), which can improve responsiveness to serious outbreaks. The Pfizer–BioNTech vaccine originally required 110 days to mass-produce (before Pfizer began to optimize the manufacturing process to only 60 days), which was substantially faster than traditional flu and polio vaccines. Within that larger timeframe, the actual production time is only about 22 days: two weeks for molecular cloning of DNA plasmids and purification of DNA, four days for DNA-to-RNA transcription and purification of mRNA, and four days to encapsulate mRNA in lipid nanoparticles followed by fill and finish. The majority of the days needed for each production run are allocated to rigorous quality control at each stage.
=== Biosynthesis === It is believed that the biosynthesis of guanacastepenes occurs via the mevalonate pathway. This pathway begins with acetyl-CoA and yields both isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). IPP and DMAPP are then converted into geranylgeranyl pyrophosphate (GGPP), the most important diterpene precursor. A cationic cyclization cascade converts GGPP into the macrocyclic intermediate β-araneosene and ultimately into the dolabellane skeleton. Dolabellane is then rearranged into the neodolabellane skeleton via stereospecific hydride and methyl shifts, thereby fixing the stereochemistry at C11 and C12 and shifting the C15 methyl group across the ring fusion. The carbon skeleton of Guanacastepene A is closely related to the dolastane and neodolabellane families. Therefore, it is assumed that the biogenesis of dolastanes proceeds via a further intramolecular cyclization of the dolabellane-derived cation, resulting in the tricyclic [5-7-6]-dolastane (guanacastane) skeleton. This basic framework is diversified through a series of oxidation reactions in which the characteristic functional groups of guanacastepenes are incorporated. The guanacastepenes characterized to date represent only a fraction of the metabolites present in the CR115 extract. The tricyclic guanacastepenes A, B, and C are considered the simplest members of this family; successive oxidation and functionalization are thought to lead to the formation of structurally more complex ring systems.
=== Wine laws and regulations === In the United States, the Alcohol and Tobacco Tax and Trade Bureau (TTB) limits the use of diammonium phosphate as a nitrogen additive to 968 mg/L (8 lbs/1000 gal) which provides 203 mg N/L of YAN. In the European Union, most countries follow the guidelines of the International Organisation of Vine and Wine (OIV) which dictates a limit of 300 mg/L. In Australia, the limit is based on the level of inorganic phosphate with a maximum limit of 400 mg/L of phosphate permitted.
At the third AU summit, held in Tripoli, Libya, in July 2005, Gaddafi called for greater integration, advocating a single AU passport, a common defence system, and a single currency, using the slogan: "The United States of Africa is the hope." His proposal for a Union of African States, a project originally conceived by Ghana's Kwame Nkrumah in the 1960s, was rejected at the 2001 Assembly of Heads of States and Government (AHSG) summit in Lusaka by African leaders who thought it "unrealistic" and "utopian". In June 2005, Libya joined the Common Market for Eastern and Southern Africa (COMESA). In March 2008 in Uganda, Gaddafi gave a speech once again urging Africa to reject foreign aid. In August 2008, Gaddafi was proclaimed "King of Kings" by a committee of traditional African leaders; they crowned him in February 2009, in a ceremony held in Addis Ababa, Ethiopia. That same month, Gaddafi was elected as the chairperson of the African Union, a position he retained for one year. In October 2010, Gaddafi apologized to African leaders for the historical enslavement of Africans by the Arab slave trade.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.